12 12
Oct Oct
2022 2022
More info

Embracing the challenge: controlled human infection and immune stimulation in drug development

09:30 to 16:45

This symposium will bring together leading clinician-scientists from both academia and industry who are actively running human challenge studies, developing new techniques to interrogate the immune response and capturing this information for therapeutic benefit. It will additionally focus on the ethical, statistical and regulatory considerations of challenge studies, seeking to stimulate debate and discussion around their conduct and future role in scientific research.

The event will take place in person in the Jacqueline du Pré Music Building at St Hilda's College. It is free to attend but please register via Eventbrite. A recording of the key sessions will be made available after the event. (There is no parking available on site. The nearest parking facility is located on St Clements. Please see the ‘Find Us’ section of the Eventbrite booking page for further information regarding transport options.)

The symposium is being organised by the Oxford Centre for Clinical Therapeutics (NDORMS, Oxford) and the Forum for Therapeutic Innovation at St Hilda's College, Oxford. It is sponsored by the British Journal of Clinical Pharmacology. The event timetable is below.

09:30 10:00: Welcome

History, Relevance and Perspective

10:00 10:10: Dr James Fullerton, Associate Professor of Clinical Therapeutic and Honorary Consultant in Clinical Pharmacology, Therapeutics and Acute and General Medicine, University of Oxford, UK: ‘Welcome’

10:10 10:40: Professor Erica Charters, Professor of the Global History of Medicine, University of Oxford, UK: ‘A history of human challenge studies: from Jenner to The Jenner’

10:40 11:10: Professor Dominic Wilkinson, Director of Medical Ethics, Oxford Uehiro Centre for Practical Ethics, University of Oxford, UK: ‘Is it right to put others at risk? The ethical basis of human challenge studies’

11:10 11:40: Dr Lars Erwig, Vice President, Scientific Innovation, Johnson & Johnson, UK: ‘Experimental medicine in big pharma and biotech’

11:40 12:10: Dr Lauren Morgan, Guest Lecturer, OxSTaR, University of Oxford and Founder, Morgan Human Systems Ltd, UK: ‘Safety first: Implementing human factors research in early phase clinical research facilities’

12:10 12:30: Panel Discussion. Chair: Dr James Fullerton

12:30 13:30: Lunch

Theory into Practice

13:30 14:00: Dr Susan Jackson, TB/COVID-19 Clinical Research Fellow, Centre for Clinical Vaccinology and Tropical Medicine, The Jenner Institute and DPhil Student, Green Templeton College, University of Oxford, UK: ‘Tackling a new foe: Controlled infection of humans with COVID-19’

14:00 14:30: Dr Maheshi Ramasamy, Associate Professor, Oxford Vaccine Group and Consultant in Infectious Diseases and Acute General Medicine, University of Oxford, UK: ‘Challenging an old enemy: Salmonella paratyphi’

14:30 15:00: Dr Katrina Pollock; Senior Clinical Research Fellow in Vaccinology and Honorary Consultant in Genitourinary Medicine, Imperial College London, UK: ‘Human lymph node responses during experimental challenge with injected immunogens; a pathway to new vaccine design’

15:00 15:15: Refreshments

15:15 15:45: Dr Matthijs Moerland / Dr Manon Jansen, Centre for Human Drug Research & Leiden University Medical Centre, The Netherlands: ‘Past and future use of keyhole limpet hemocyanin challenges in human clinical pharmacology studies’

15:45 16:15: Dr Daren Austin OBE, Global Senior Consultant, Clinical Pharmacology Experimental Medicine, GlaxoSmithKline, UK: ‘Designing, interpreting and modelling human challenge studies’

16:15 16:45: Panel Discussion and Close. Chair: Prof Duncan Richards, Climax Professor of Clinical Therapeutics